Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.
10.3857/roj.2013.31.4.199
- Author:
Ji Hyeon JOO
1
;
Yeon Joo KIM
;
Young Seok KIM
;
Eun Kyung CHOI
;
Jong Hoon KIM
;
Sang Wook LEE
;
Si Yeol SONG
;
Sang Min YOON
;
Su Ssan KIM
;
Jin Hong PARK
;
Yuri JEONG
;
Hanjong AHN
;
Choung Soo KIM
;
Jae Lyun LEE
;
Seung Do AHN
Author Information
1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ysk@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Prostate neoplasms;
Intensity-modulated radiotherapy;
Complications
- MeSH:
Cohort Studies;
Cone-Beam Computed Tomography;
Humans;
Neoplasm Grading;
Pelvis;
Prostate*;
Prostate-Specific Antigen;
Prostatic Neoplasms*;
Radiotherapy, Intensity-Modulated*;
Survival Rate
- From:Radiation Oncology Journal
2013;31(4):199-205
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To assess the clinical efficacy and toxicity of whole pelvic intensity-modulated radiotherapy (WP-IMRT) for high-risk prostate cancer. MATERIALS AND METHODS: Patients with high-risk prostate cancer treated between 2008 and 2013 were reviewed. The study included patients who had undergone WP-IMRT with image guidance using electronic portal imaging devices and/or cone-beam computed tomography. The endorectal balloon was used in 93% of patients. Patients received either 46 Gy to the whole pelvis plus a boost of up to 76 Gy to the prostate in 2 Gy daily fractions, or 44 Gy to the whole pelvis plus a boost of up to 72.6 Gy to the prostate in 2.2 Gy fractions. RESULTS: The study cohort included 70 patients, of whom 55 (78%) had a Gleason score of 8 to 10 and 50 (71%) had a prostate-specific antigen level > 20 ng/mL. The androgen deprivation therapy was combined in 62 patients. The biochemical failure-free survival rate was 86.7% at 2 years. Acute any grade gastrointestinal (GI) and genitourinary (GU) toxicity rates were 47% and 73%, respectively. The actuarial rate of late grade 2 or worse toxicity at 2 years was 12.9% for GI, and 5.7% for GU with no late grade 4 toxicity. CONCLUSION: WP-IMRT was well tolerated with no severe acute or late toxicities, resulting in at least similar biochemical control to that of the historic control group with a small field. The long-term efficacy and toxicity will be assessed in the future, and a prospective randomized trial is needed to verify these findings.
